1.中国中医科学院 中药研究所,北京 100700
2.北京中医药大学 东直门医院通州院区,北京 101100
郭诗韵,在读硕士,从事中药药理学及中药复方配伍科学性研究,E-mail:gshiyun000@163.com
翁小刚,研究员,博士生导师,从事中药复方药代动力学与药效学研究,E-mail:xgweng@icmm.ac.cn
邓志灏,副主任医师,从事中医药防治肛肠疾病研究及临床,E-mail:dengzhihaozyy@163.com
收稿:2024-07-15,
网络出版:2024-10-09,
纸质出版:2024-12-05
移动端阅览
郭诗韵,郭雨轩,孙奕等.基于PPARγ信号通路和T细胞免疫调节探讨戊己丸对炎症性肠病大鼠的治疗作用[J].中国实验方剂学杂志,2024,30(23):237-245.
GUO Shiyun,GUO Yuxuan,SUN Yi,et al.Exploration of Therapeutic Effect of Wujiwan on Inflammatory Bowel Disease in Rats Based on PPARγ Signaling Pathway and T-cell Immunoregulation[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(23):237-245.
郭诗韵,郭雨轩,孙奕等.基于PPARγ信号通路和T细胞免疫调节探讨戊己丸对炎症性肠病大鼠的治疗作用[J].中国实验方剂学杂志,2024,30(23):237-245. DOI: 10.13422/j.cnki.syfjx.20241644.
GUO Shiyun,GUO Yuxuan,SUN Yi,et al.Exploration of Therapeutic Effect of Wujiwan on Inflammatory Bowel Disease in Rats Based on PPARγ Signaling Pathway and T-cell Immunoregulation[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(23):237-245. DOI: 10.13422/j.cnki.syfjx.20241644.
目的
2
从过氧化物酶体增殖物激活受体
γ
(PPAR
γ
)信号通路和T细胞免疫方面探讨戊己丸对大鼠炎症性肠病(IBD)的药效及药效机制,为中医药治疗IBD提供参考。
方法
2
对35只大鼠采用2,4,6-三硝基苯磺酸(TNBS)灌肠诱导大鼠急性炎症性肠病,24 h后,模型动物分正常组、模型组、戊己丸给药组及阳性药组,各组连续灌胃给药8 d后解剖大鼠,比较大鼠结肠组织的疾病活动指数(DAI)、结肠黏膜损伤指数(CMDI)、脾脏指数;酶联免疫吸附测定法(ELISA)检测血清中白细胞介素-1
β
(IL-1
β
)、白细胞介素-10(IL-10)、肿瘤坏死因子
-α
(TNF-
α
)水平,实时荧光定量聚合酶链式反应(Real-time PCR)测定结肠组织中T-box家族的新型转录因子(T-bet)、Gata转录因子家族的转录因子3(Gata3)的mRNA表达
水平;蛋白免疫印迹法(Western blot)检测大鼠结肠PPAR
γ
、T-bet、核转录因子-
κ
B p65(NF-
κ
B p65)的蛋白表达水平。
结果
2
IBD大鼠模型建造成功,且与模型组比较,戊己组大鼠DAI评分降低,CMDI评分降低(
P
<
0.05),脾脏指数降低,血清中TNF-
α
含量显著降低(
P
<
0.01),IL-10含量显著升高(
P
<
0.01),结肠组织中T-bet mRNA含量升高,Gata3 mRNA含量明显升高(
P
<
0.05),PPAR
γ
蛋白表达量明显升高(
P
<
0.05),T-bet、NF-
κ
B p65蛋白表达明显降低(
P
<
0.05,
P
<
0.01)。
结论
2
戊己丸可通过激活或上调IBD大鼠PPAR
γ
的表达抑制促炎因子生成,参与炎症免疫进程,减轻炎症反应,作用机制与PPAR
γ
调节NF-
κ
B通路及增强Th2细胞转录表达、减少Th1细胞转录有关。
Objective
2
This study explores the efficacy and pharmacological mechanism of Wujiwan in rats with inflammatory bowel disease (IBD) from the perspectives of the peroxisome proliferator-activated receptor
γ
(PPAR
γ
) signaling pathway and T-cell immunity, providing reference for the treatment of IBD with traditional Chinese medicine.
Method
2
The study involved administering 2,4,6-trinitrobenzenesulfonic acid (TNBS) enemas to 35 rats to induce acute IBD. After 24 hours, the animals were divided into the following groups: normal group, model group, Wujiwan treatment group, and positive drug control group. Each group received gastric gavage for 8 consecutive days before the rats were dissected to compare the disease activity index (DAI) of the rat colon tissue, the colon mucosal damage index (CMDI), and the spleen index. Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of interleukin-1
β
(IL-1
β
), interleukin-10 (IL-10), and tumor necrosis factor-
α
(TNF-
α
) in the serum. Quantitative real-time polymerase chain reaction (Real-time PCR) was used to dete
rmine the mRNA expression levels of T-bet (T-box expressed in T cells) and Gata3 (Gata-binding protein-3) in the colon tissue. Western blot analysis was conducted to detect the protein expression levels of PPAR
γ
, T-bet, and nuclear factor
-κ
B p65 (NF-
κ
B p65) in the rat colon.
Result
2
The rat model of IBD was successfully established. Compared with the model group, the Wujiwan treatment group showed reduced DAI, CMDI, and spleen index, decreased content of TNF-
α
in the serum(
P
<
0.01), significantly increased content of IL-10(
P
<
0.01), and elevated mRNA content of T-bet and Gata3(
P
<
0.05) in the colon tissue. The expression of PPAR
γ
protein was augmented(
P
<
0.05), and the expression of T-bet and NF-
κ
B p65 protein was decreased(
P
<
0.05,
P
<
0.01).
Conclusion
2
Wujiwan activates or upregulates PPAR
γ
expression in IBD rats to inhibit the generation of pro-inflammatory factors, participates in the inflammatory immune process, and alleviates inflammatory reactions. Its mechanism may involve regulating the NF-
κ
B pathway through PPAR
γ
, enhancing Th2 cell transcription expression, and reducing Th1 cell transcription.
SOETIKNO R , KALTENBACH T , MCQUAID K R , et al . Paradigm shift in the surveillance and management of dysplasia in inflammatory bowel disease (west) [J]. Dig Endosc , 2016 , 28 ( 3 ): 266 - 273 .
卞莹莹 , 王洁 , 李安 , 等 . 炎症性肠病的药物治疗现状 [J]. 药学实践杂志 , 2017 , 35 ( 3 ): 197 - 200,228 .
SINGH S , AL-DARMAKI A , FROLKIS A D , et al . Postoperative mortality among patients with inflammatory bowel diseases: A systematic review and meta-analysis of population-based studies [J]. Gastroenterology , 2015 , 149 ( 4 ): 928 - 937 .
MAK W Y , ZHAO M , NG S C , et al . The epidemiology of inflammatory bowel disease: East meets west [J]. J Gastroenterol Hepatol , 2020 , 35 ( 3 ): 380 - 389 .
凌海慧 , 梁棻 , 刘蓉 , 等 . 中医药保护肠黏膜屏障治疗炎症性肠病的研究进展 [J]. 天津中医药 , 2018 , 35 ( 9 ): 718 - 720 .
黄鹤飞 , 强伟杰 , 杨庆 , 等 . 戊己丸对炎症后肠易激综合征大鼠脑肠肽的调控作用 [J]. 中国实验动物学报 , 2018 , 26 ( 3 ): 265 - 271 .
门薇 , 陈颖 , 杨庆 , 等 . 不同配伍戊己丸的黄连生物碱在人源肠道菌群中的代谢研究 [J]. 中国中药杂志 , 2013 , 38 ( 3 ): 417 - 421 .
翁小刚 , 李玉洁 , 杨庆 , 等 . 戊己丸不同配比方对大鼠体外CYP3A1/3A2酶活性的影响 [J]. 中国中药杂志 , 2010 , 35 ( 9 ): 1164 - 1169 .
郭雨轩 , 郭诗韵 , 朱晓新 , 等 . 戊己丸现代研究进展 [J]. 中华中医药学刊 , 2023 , 41 ( 10 ): 173 - 178 .
马秀兰 , 王秀萍 , 王佳林 , 等 . 大鼠溃疡性结肠炎模型的建立 [J]. 中医药临床杂志 , 2021 , 33 ( 9 ): 1754 - 1759 .
钟宇 , 郑学宝 , 叶华 , 等 . 白头翁汤对溃疡性结肠炎大鼠的疗效及免疫机制的影响 [J]. 中国实验方剂学杂志 , 2019 , 25 ( 12 ): 15 - 21 .
安阿玥 . 肛肠病学 [M]. 3版 . 北京 : 人民卫生出版社 , 2015 : 341 .
SUN L , SU Y , JIAO A , et al . T cells in health and disease [J]. Signal Transduct Target Ther , 2023 , 8 ( 1 ): 235 .
IMAM T , PARK S , KAPLAN M H , et al . Effector T helper cell subsets in inflammatory bowel diseases [J]. Front Immunol , 2018 , 9 : 1212 .
WAN Y Y . GATA3:A master of many trades in immune regulation [J]. Trends Immunol , 2014 , 35 ( 6 ): 233 - 242 .
LIU Y , WANG J , LUO S , et al . The roles of PPAR γ and its agonists in autoimmune diseases: A comprehensive review [J]. J Autoimmun , 2020 , 113 : 102510 .
YAO J , PAN D , ZHAO Y , et al . Wogonin prevents lipopolysaccharide-induced acute lung injury and inflammation in mice via peroxisome proliferator-activated receptor gamma-mediated attenuation of the nuclear factor-kappaB pathway [J]. Immunology , 2014 , 143 ( 2 ): 241 - 257 .
刘滨 , 刘雅清 , 宋红新 , 等 . 黄芩汤对溃疡性结肠炎小鼠Th17/Treg、Th1/Th2细胞平衡的影响 [J]. 中国实验方剂学杂志 , 2022 , 28 ( 22 ): 7 - 15 .
侯朝军 . 柳氮磺胺吡啶联合康复新液对溃疡性结肠炎患者肠道黏膜NF- κ B、TLR-4表达及免疫功能的影响 [J]. 反射疗法与康复医学 , 2022 , 3 ( 10 ): 119 - 121 .
YOUSEFI-AHMADIPOUR A , EBRAHIMI-BAROUGH S , NIKNIA S , et al . Therapeutic effects of combination of platelet lysate and sulfasalazine administration in TNBS-induced colitis in rat [J]. Biomed Pharmacother , 2020 , 125 : 109949 .
QUAGLIO A E , CASTILHO A C , DI STASI L C . Experimental evidence of heparanase, Hsp70 and NF- κ B gene expression on the response of anti-inflammatory drugs in TNBS-induced colonic inflammation [J]. Life Sci , 2015 , 141 : 179 - 187 .
ELHEFNAWY E A , ZAKI H F , El MARAGHY N N , et al . Genistein and/or sulfasalazine ameliorate acetic acid-induced ulcerative colitis in rats via modulating INF- γ /JAK1/STAT1/IRF-1,TLR-4/NF- κ B/IL-6, and JAK2/STAT3/COX-2 crosstalk [J]. Biochem Pharmacol , 2023 , 214 : 115673 .
叶斌 , 邹秀丽 , 刘廉 . 甲钴胺片联合醋酸泼尼松龙治疗周围性面瘫效果及对T淋巴细胞亚群的影响 [J]. 中外医疗 , 2024 , 43 ( 3 ): 87 - 90 .
尤鹏 , 刘玉兰 , 刘安楠 . 柳氮磺胺吡啶和氢化泼尼松对大鼠结肠炎模型调节性T细胞的影响 [J]. 免疫学杂志 , 2006 , 22 ( 1 ): 72 - 75 .
BRUSCOLI S , FEBO M , RICCARDI C , et al . Glucocorticoid therapy in inflammatory bowel disease:Mechanisms and clinical practice [J]. Front Immunol , 2021 , 12 : 691480 .
0
浏览量
68
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
